This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
Sandip P. Vasavada, MD
Advertisement
Articles by Sandip P. Vasavada, MD
Advertisement
Latest Updated Articles
- Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions
Published: February 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
2
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
3
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
4
Frequent Continuous Glucose Monitoring Linked to Greater HbA1C Reductions in Adults With T2D
5
